ÃÖ¹Îö
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ºÎÀÎÁ¾¾çÇÐ,·Îº¿¼ö¼ú,ÇÏÀÌÆå(HIPEC)
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
32
±¹³»
Clinical significance of variants of unknown significances in BRCA genes
31
ÇØ¿Ü
Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas
30
ÇØ¿Ü
Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
29
±¹³»
Management of gynecolgic malignancies in old age
28
ÇØ¿Ü
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
27
ÇØ¿Ü
A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution
26
±¹³»
Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube
25
±¹³»
Minimal deviation adenocarcinoma (Adenoma malignum) of the uterine cervix: Clinicopathological analysis of 17 cases
24
ÇØ¿Ü
Clinicopathologic characteristics of double primary endometrial and colorectal cancers in a single institution
23
ÇØ¿Ü
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients with Ovarian Cancer
1
2
3
4
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729